177 related articles for article (PubMed ID: 20175591)
1. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Rendas-Baum R; Yang M; Gricar J; Wallenstein GV
Appl Health Econ Health Policy; 2010; 8(2):129-40. PubMed ID: 20175591
[TBL] [Abstract][Full Text] [Related]
2. [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review].
Marais-Thomas H; Chapelle F; de Vaux-Boitouzet V; Bouvet C
Encephale; 2024 Apr; 50(2):211-232. PubMed ID: 37821319
[TBL] [Abstract][Full Text] [Related]
3. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
4. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
Endicott J; McLaughlin TP; Grudzinski AN
J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
[TBL] [Abstract][Full Text] [Related]
5. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
6. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
Svojanovská K
Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
[TBL] [Abstract][Full Text] [Related]
7. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
9. Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.
Halbreich U; Kahn LS
Expert Opin Pharmacother; 2003 Nov; 4(11):2065-78. PubMed ID: 14596660
[TBL] [Abstract][Full Text] [Related]
10. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Nurnberg HG; Hensley PL; Thompson PM; Paine SS
Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
12. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors for premenstrual syndrome.
Brown J; O' Brien PM; Marjoribanks J; Wyatt K
Cochrane Database Syst Rev; 2009 Apr; (2):CD001396. PubMed ID: 19370564
[TBL] [Abstract][Full Text] [Related]
14. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
[TBL] [Abstract][Full Text] [Related]
15. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
Pearlstein T; Yonkers KA
Expert Opin Pharmacother; 2002 Jul; 3(7):979-91. PubMed ID: 12083997
[TBL] [Abstract][Full Text] [Related]
16. The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
Romano S; Judge R; Dillon J; Shuler C; Sundell K
Clin Ther; 1999 Apr; 21(4):615-33; discussion 613. PubMed ID: 10363729
[TBL] [Abstract][Full Text] [Related]
17. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Shah NR; Jones JB; Aperi J; Shemtov R; Karne A; Borenstein J
Obstet Gynecol; 2008 May; 111(5):1175-82. PubMed ID: 18448752
[TBL] [Abstract][Full Text] [Related]
18. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder.
Jarvis CI; Lynch AM; Morin AK
Ann Pharmacother; 2008 Jul; 42(7):967-78. PubMed ID: 18559957
[TBL] [Abstract][Full Text] [Related]
19. Treating premenstrual dysphoric disorder using serotonin agents.
Lin J; Thompson DS
J Womens Health Gend Based Med; 2001 Oct; 10(8):745-50. PubMed ID: 11703886
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
